84752-20-5 Usage
Uses
Used in Dye and Pigment Production:
5-Bromo-3-nitro-benzene-1,2-diamine is utilized as a key intermediate in the synthesis of dyes and pigments. Its chemical structure contributes to the color and stability of these products, making it an essential component in this application.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 5-Bromo-3-nitro-benzene-1,2-diamine serves as a building block for the development of various drugs. Its reactivity allows for the creation of new compounds with potential therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Research and Development:
5-Bromo-3-nitro-benzene-1,2-diamine is also employed in research settings to explore its chemical properties and potential applications. Its sensitivity to light, heat, and shock provides a unique platform for studying the effects of these factors on chemical reactions and compound stability.
Check Digit Verification of cas no
The CAS Registry Mumber 84752-20-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,4,7,5 and 2 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 84752-20:
(7*8)+(6*4)+(5*7)+(4*5)+(3*2)+(2*2)+(1*0)=145
145 % 10 = 5
So 84752-20-5 is a valid CAS Registry Number.
84752-20-5Relevant academic research and scientific papers
BROMODOMAIN INHIBITOR
-
Paragraph 0288, (2016/10/31)
The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS
-
, (2012/04/18)
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kβ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.
